导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -23.33% | 4480/4773 |
| 近一周 | -4.94% | 5175/5462 |
| 近一月 | -5.46% | 3240/5421 |
| 近一季 | -3.15% | 1356/5209 |
| 近半年 | -21.43% | 4451/4920 |
| 近一年 | -29.83% | 4191/4366 |
| 近两年 | -11.68% | 2946/2954 |
| 近三年 | -45.14% | 2244/2253 |
| 成立以来 | -4.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-11.09% 4440/4961 |
-20.40% 4877/5312 |
- - |
- - |
| 2025 | -3.01% 3347/4813 |
-3.97% 3111/3635 |
-3.37% 3430/4076 |
23.16% 1570/4524 |
-15.13% 4357/4813 |
| 2024 | -4.13% 2231/3463 |
-7.37% 2149/2808 |
-10.61% 2462/3014 |
33.54% 82/3129 |
-13.30% 3071/3463 |
| 2023 | -29.92% 2059/2656 |
-4.74% 2115/2280 |
-8.59% 2004/2385 |
0.87% 333/2515 |
-20.22% 2493/2655 |
| 2022 | -10.76% 217/2207 |
7.68% 26/1919 |
-7.94% 1893/2016 |
-5.23% 69/2113 |
-5.01% 1913/2208 |
| 2021 | -5.79% 984/1822 |
-1.09% 429/1255 |
-7.14% 1281/1330 |
2.86% 425/1466 |
-0.29% 1218/1822 |
| 2020 | -2.01% 955/1250 |
-11.95% 862/1028 |
5.74% 876/1067 |
10.67% 526/1164 |
-4.91% 1137/1184 |
| 2019 | 34.62% 395/1092 |
30.64% 238/754 |
-8.87% 615/804 |
-0.49% 597/850 |
13.64% 28/918 |
| 2018 | -22.61% 249/834 |
- - |
- - |
- - |
-4.05% 26/691 |
| 2017 | 17.41% 228/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.19% 431/605 |
- - |
- - |
- - |
- - |
| 2015 | 29.99% 77/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 鹏华中证800地产指数(LOF)A VS. 长安沪深300非周期A(740101) |